AI Science Tracker
EN

Artificial intelligence (AI) for breast cancer screening: BreastScreen population-based cohort study of cancer detection.

Not stated in the abstract reviewed · 28 Feb 2023 · medicine

Discovery

Artificial intelligence (AI) for breast cancer screening: BreastScreen population-based cohort study of cancer detection.

Source check: Source checked. Not independent scientific confirmation.

Finding: A commercially available mammography AI algorithm scored cancer likelihood and was compared with practicing radiologists; simulated AI-radiologist arbitration estimated workload and screening outcomes. External evaluation of 108,970 consecutive screens with registry-ascertained interval cancers: AI AUC .83 vs radiologists .93; at prospective threshold sensitivity .67 vs .68 but specificity .81 vs .97. AI-plus-reader simulation reduced reading volume 41.4%, with slightly lower cancer detection rate but detected interval cancers missed at original reading. Real-world retrospective population screening cohort external validation, outcomes linked to registry; simulations are not prospective deployment.

Technology: A commercially available mammography AI algorithm scored cancer likelihood and was compared with practicing radiologists; simulated AI-radiologist arbitration estimated workload and screening outcomes.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A commercially available mammography AI algorithm scored cancer likelihood and was compared with practicing radiologists; simulated AI-radiologist arbitration estimated workload and screening outcomes.
Test and result
External evaluation of 108,970 consecutive screens with registry-ascertained interval cancers: AI AUC .83 vs radiologists .93; at prospective threshold sensitivity .67 vs .68 but specificity .81 vs .97. AI-plus-reader simulation reduced reading volume 41.4%, with slightly lower cancer detection rate but detected interval cancers missed at original reading.
Limitation / still unknown
Real-world retrospective population screening cohort external validation, outcomes linked to registry; simulations are not prospective deployment.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9996220/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.